Phase II Randomized, Double-Blind, Placebo-Controlled Study of BMS-188667 (CTLA4Ig) in Patients With Psoriasis Vulgaris

NCT00287547 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
144
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Bristol-Myers Squibb